Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.
- The ARCT-810 Phase 2 study is a randomized, double-blind, placebo-controlled, nested single and multiple ascending dose design for adolescents and adults with OTC deficiency.
- We are pleased to initiate this multiple dose Phase 2 clinical trial of ARCT-810 in OTC deficiency patients.
- Advancement to a Phase 2 study is supported by the safety results from our ARCT-810 Phase 1 trial in Healthy Volunteers, said Steve Hughes, M.D., Chief Medical Officer of Arcturus.
- Ornithine Transcarbamylase (OTC) deficiency is a serious urea cycle disorder with a prevalence of approximately 10,000 people worldwide.